This live web event has ended. Thank you for attending.
The oral absorption process consists of numerous hurdles that a drug needs to conquer before reaching systemic circulation. Drug release and absorption are quite complex considering the dynamic nature of the human gastrointestinal (GI) tract. Depending on (i) the desired systemic exposure and (ii) the associated pharmacodynamic effect, drug release can be triggered across the human GI tract as such to deliver the drug in a specific region at a specific release rate. In the particular interest of locally-acting drugs, numerous drug delivery strategies are developed to target drug release in assigned regions of the colon especially when interested in the treatment of inflammatory bowel diseases (e.g., ulcerative colitis). Reaching the most distal parts of the human GI tract is challenging as extra barriers need to be conquered compared to oral drug delivery in the more proximal parts. In the following series of webinars as organized by the Oral Biopharmaceutics and Modeling (OBAM) community of AAPS, an in-depth overview of (i) physiological aspects of the colonic environment, (ii) colonic-targeted formulations and (iii) predictions towards colonic absorption will be thoroughly discussed.
Part 2: Developing Colon-targeting Formulations
There are two major reasons for developing colon-targeting formulations. The first is to create extended-release formulations for rapidly absorbed immediate-release products in order to limit number of daily doses to one or two. Such products typically rely on their good colonic absorption. The second is the targeted release of drugs in colon for the treatment of colonic diseases, in which case the absorption from the colon might not be desired. This webinar will be focus on formulation design and strategies in pursuit of colonic release.
- Which physico-chemical properties of the drug determine its potential for colonic absorption.
- Type of colon-targeting formulations.
- Formulation strategies to overcome the hurdles associated with colonic delivery – low fluid content, residual bile salts, high pH, etc.